Edgewise Therapeutics, Inc.
EWTX
$44.17
$0.992.29%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -16.96% | 2.40% | -23.48% | -12.60% | 11.48% |
| Total Depreciation and Amortization | 1.19% | 2.61% | 0.88% | 0.53% | 2.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.05% | -8.22% | 39.19% | 9.02% | -22.51% |
| Change in Net Operating Assets | 413.28% | -168.57% | 474.75% | 72.35% | 46.11% |
| Cash from Operations | 0.17% | -10.24% | -10.97% | -6.73% | 13.95% |
| Capital Expenditure | 87.69% | -256.16% | 17.98% | -78.00% | -13.64% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2,815.78% | -94.60% | 39.18% | 122.09% | -468.93% |
| Cash from Investing | 3,126.06% | -95.11% | 39.33% | 122.02% | -469.42% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -74.64% | 206.24% | 139.60% | -99.12% | 8,223.44% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 200.00% |
| Cash from Financing | -74.64% | 206.24% | 139.60% | -99.12% | 8,367.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 239.99% | -284.46% | 482.72% | 139.88% | -178.95% |